Mabwell Shanghai Bioscience Co Ltd

Mabwell Shanghai Bioscience Co Ltd is expanding its focus on small-nucleic-acid therapeutics and international partnerships, positioning itself for a potential transition from a domestic biotech firm to a global pharmaceutical entity.

Mabwell Shanghai Bioscience Co Ltd’s stock surged 20% after announcing a strategic partnership with Kalexo Bio, a US-based venture, granting exclusive rights to develop and commercialize its dual-target small-nucleic-acid candidate, 2MW7141, in exch…

Mabwell Shanghai Bioscience Co Ltd is a leading biotech company in China, riding the wave of innovation in AI hardware and pharmaceuticals, with institutional and international investors taking note of its potential for future success.

Mabwell Shanghai Bioscience Co Ltd is a biotech giant making strategic moves, including a $596 million deal with Alphabet’s Calico, to drive innovation and growth in the industry.

Mabwell Shanghai Bioscience Co Ltd is a leading biotech company in China, showcasing resilience and innovation as it navigates the country’s rapidly evolving biotech landscape.

Mabwell Shanghai Bioscience Co Ltd is a prominent biotech player in China, poised to capitalize on the country’s rapidly evolving biotech sector with a strong market cap and strategic focus on innovation.

Mabwell Shanghai Bioscience Co Ltd stands out as a beacon of innovation and resilience in the biotech sector, navigating market turbulence and regulatory scrutiny while showcasing its clinical research achievements at the prestigious ASCO 2025 conference.